Raquel Santos-Toscano

Raquel Santos-Toscano

Auto-generated profile, based on publicly available information

Raquel Santos-Toscano

Department of Psychobiology, School of Psychology, National University for Distance Learning (UNED), Madrid, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
RSRaquel Santos-Toscano
Raquel Santos-Toscano
ÉBÉrika Borcel
Érika Borcel
MUMarcos Ucha
Marcos Ucha
JOJavier Orihuel
Javier Orihuel
RCRoberto Capellán
Roberto Capellán
AHAlejandro Higuera-Matas
Alejandro Higuera-Matas

19 March 2019 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MUMarcos Ucha
Marcos Ucha
SCSantiago M Coria
Santiago M Coria
ANAdrián E Núñez
Adrián E Núñez
RSRaquel Santos-Toscano
Raquel Santos-Toscano
DRDavid Roura-Martínez
David Roura-Martínez
EAEmilio Ambrosio
Emilio Ambrosio
Addiction is a chronic disorder with a high risk of relapse. The neural mechanisms mediating addictions require protein synthesis, which could be relevant for the development of more effective treatments. The mTOR signaling pathway regulates protein synthesis processes that have recently been linked to the development of drug addiction. To assess the effects of morphine self-administration and its subsequent extinction on the expression of several genes that act in this pathway, and on the levels of specific phosphoproteins (Akt, Gsk3α/β, mTOR, PDK1 and p70 S6 kinase) in the amygdala, nucleus accumbens, and the prefrontal cortex. Male Lewis rats underwent morphine self-administration (1 mg/kg) for 19 days. They subsequently were submitted to extinction training for 15 days. Rats were killed either after self-administration or extinction, their brains extracted, and gene expression or phosphoprotein levels were assessed. We found an increase in Raptor and Eif4ebp2 expression in the amygdala of rats that self-administered morphine, even after extinction. The expression of Insr in the amygdala of control animals decreased over time while the opposite effect was seen in the rats that self-administered morphine. Our results suggest that morphine self-administration affects the gene expression of some elements of the translational machinery in the amygdala.

1 January 2016 in Neurobiology of Learning and Memory
Verified
Journal Article
Closed access
MSMaria J Simon
Maria J Simon
AHA. Higuera-Matas
A. Higuera-Matas
DRD. Roura-Martinez
D. Roura-Martinez
MUM. Ucha
M. Ucha
RSR. Santos-Toscano
R. Santos-Toscano
APA. Puerto
A. Puerto

1 June 2020 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
RSRaquel Santos-Toscano
Raquel Santos-Toscano
MUMarcos Ucha
Marcos Ucha
ÉBÉrika Borcel
Érika Borcel
EAEmilio Ambrosio
Emilio Ambrosio
AHAlejandro Higuera-Matas
Alejandro Higuera-Matas

11 February 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
RSRaquel Santos‐Toscano
Raquel Santos‐Toscano
Amira GuirguisAmira Guirguis
Amira Guirguis
CDColin Davidson
Colin Davidson
Novel psychoactive substances (NPS) are new drugs of abuse. Over the last 10 years 50–100 new NPS have been detected for the first time each year. This has led to numerous deaths and challenges to healthcare providers and law‐makers worldwide. We review preclinical studies of NPS and discuss how these studies have influenced legislative decisions. We focus on the UK legal system but include experiences from Europe. We reviewed manuscripts from 2008–2019 and have summarised the in vitro and in vivo data on NPS, highlighting how these studies define pharmacological mechanisms and how they might predict harm in humans. We found that only a small percentage of NPS have been examined in preclinical studies. Most preclinical studies of NPS focus on basic pharmacological mechanisms (46% of studies reviewed) and/or addictive liability (32%) rather than toxicity and harm (24%). Very few preclinical studies into NPS include data from chronic dosing schedules (9%) or female rodents (4%). We conclude that preclinical studies can predict harm to humans, but most of the predictions are based on basic pharmacology rather than demonstrated toxicity. Some of these studies have been used to make changes to the law in the UK and Europe and perhaps, because of the paucity of toxicology data, most NPS have been placed in the highly dangerous schedule 1 or Class A category in the UK. We suggest that in silico studies and high throughput toxicology screens might be the most economical way forward to rapidly screen the health harms of NPS.